Editas Medicine, Inc. (EDIT)
2.62
+0.10
(+3.97%)
USD |
NASDAQ |
Oct 02, 16:00
2.60
-0.02
(-0.76%)
Pre-Market: 20:00
Editas Medicine Enterprise Value : 261.86M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 261.86M |
| October 01, 2026 | 246.50M |
| September 30, 2026 | 254.18M |
| September 29, 2026 | 257.25M |
| September 28, 2026 | 244.97M |
| September 25, 2026 | 255.71M |
| September 24, 2026 | 281.81M |
| September 23, 2026 | 272.60M |
| September 22, 2026 | 307.91M |
| September 21, 2026 | 294.10M |
| September 18, 2026 | 274.14M |
| September 17, 2026 | 277.21M |
| September 16, 2026 | 275.67M |
| September 15, 2026 | 263.39M |
| September 14, 2026 | 280.28M |
| September 11, 2026 | 274.14M |
| September 10, 2026 | 266.46M |
| September 09, 2026 | 284.88M |
| September 08, 2026 | 324.80M |
| September 04, 2026 | 355.51M |
| September 03, 2026 | 332.48M |
| September 02, 2026 | 332.48M |
| September 01, 2026 | 330.94M |
| August 31, 2026 | 329.41M |
| August 28, 2026 | 344.76M |
| Date | Value |
|---|---|
| August 27, 2026 | 366.26M |
| August 26, 2026 | 347.83M |
| August 25, 2026 | 363.19M |
| August 24, 2026 | 320.20M |
| August 21, 2026 | 337.09M |
| August 20, 2026 | 310.98M |
| August 19, 2026 | 358.58M |
| August 18, 2026 | 301.77M |
| August 17, 2026 | 295.63M |
| August 14, 2026 | 292.56M |
| August 13, 2026 | 291.03M |
| August 12, 2026 | 295.63M |
| August 11, 2026 | 312.52M |
| August 10, 2026 | 291.03M |
| August 07, 2026 | 301.77M |
| August 06, 2026 | 304.84M |
| August 05, 2026 | 281.81M |
| August 04, 2026 | 284.88M |
| August 03, 2026 | 266.46M |
| July 31, 2026 | 255.71M |
| July 30, 2026 | 272.60M |
| July 29, 2026 | 258.78M |
| July 28, 2026 | 261.86M |
| July 27, 2026 | 271.07M |
| July 24, 2026 | 258.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Recursion Pharmaceuticals, Inc. | 1.716B |
| Geron Corp. | 720.00M |
| Halozyme Therapeutics, Inc. | 14.44B |
| Novavax, Inc. | 1.302B |
| AVITA Medical, Inc. | 430.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.23M |
| Revenue (Quarterly) | 11.89M |
| Total Expenses (Quarterly) | 30.12M |
| EPS Diluted (Quarterly) | -0.1528 |
| Gross Profit Margin (Quarterly) | 96.50% |
| Profit Margin (Quarterly) | -153.3% |
| Earnings Yield | -28.42% |
| Normalized Earnings Yield | -30.44 |